Use of Statins in Patients with Chronic Liver Disease and Cirrhosis

Current Views and Prospects

Jose Ignacio Vargas, Marco Arrese, Vijay Shah, Juan Pablo Arab

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.

Original languageEnglish (US)
Article number43
JournalCurrent Gastroenterology Reports
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver Cirrhosis
Liver Diseases
Chronic Disease
Portal Hypertension
Hepatocellular Carcinoma
Fibrosis
Chemical and Drug Induced Liver Injury
Prescriptions
Public Health
Physicians
Liver
Research
Pharmaceutical Preparations

Keywords

  • Chronic liver diseases
  • Cirrhosis
  • Drug-induced liver injury
  • Hepatocellular carcinoma
  • HMG-CoA reductase inhibitors
  • Portal hypertension
  • Statins
  • Variceal bleeding

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Use of Statins in Patients with Chronic Liver Disease and Cirrhosis : Current Views and Prospects. / Vargas, Jose Ignacio; Arrese, Marco; Shah, Vijay; Arab, Juan Pablo.

In: Current Gastroenterology Reports, Vol. 19, No. 9, 43, 01.09.2017.

Research output: Contribution to journalReview article

@article{a19600c196534e02bf06b0a897879e2d,
title = "Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects",
abstract = "Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.",
keywords = "Chronic liver diseases, Cirrhosis, Drug-induced liver injury, Hepatocellular carcinoma, HMG-CoA reductase inhibitors, Portal hypertension, Statins, Variceal bleeding",
author = "Vargas, {Jose Ignacio} and Marco Arrese and Vijay Shah and Arab, {Juan Pablo}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11894-017-0584-7",
language = "English (US)",
volume = "19",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - Use of Statins in Patients with Chronic Liver Disease and Cirrhosis

T2 - Current Views and Prospects

AU - Vargas, Jose Ignacio

AU - Arrese, Marco

AU - Shah, Vijay

AU - Arab, Juan Pablo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.

AB - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.

KW - Chronic liver diseases

KW - Cirrhosis

KW - Drug-induced liver injury

KW - Hepatocellular carcinoma

KW - HMG-CoA reductase inhibitors

KW - Portal hypertension

KW - Statins

KW - Variceal bleeding

UR - http://www.scopus.com/inward/record.url?scp=85026643973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026643973&partnerID=8YFLogxK

U2 - 10.1007/s11894-017-0584-7

DO - 10.1007/s11894-017-0584-7

M3 - Review article

VL - 19

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 9

M1 - 43

ER -